RxDoctor Payments Data

Mary Claire Paicopolis, MD

Cardiovascular Disease · Laconia, NHNPI 1114018322

Payments from drug & device makers

$211in general payments, 2019–2025

Across 13 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$72
  • Abbott$40
  • E.r. Squibb & Sons, L.L.C.$26
  • Johnson & Johnson$23
  • AstraZeneca$19
  • Novartis$18
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$211 in reported general payments places this provider in the 20th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$398,476
Medicare patients
886
Services billed
4,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban539$699,298
XareltoRivaroxaban94$128,271
EntrestoSacubitril/Valsartan84$114,988
JardianceEmpagliflozin82$112,590
OzempicSemaglutide57$66,511
Repatha SureclickEvolocumab31$33,364
MultaqDronedarone Hcl13$27,254
BrilintaTicagrelor35$23,918
JanuviaSitagliptin Phosphate14$22,863
Metoprolol Succinate1,010$15,518
Repatha SyringeEvolocumab22$15,086
Atorvastatin Calcium1,472$14,039
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,269
TrulicityDulaglutide12$11,499
Pantoprazole Sodium567$7,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$23$128,27194 claims
NovartisEntresto$18$114,98884 claims
AstraZenecaBrilinta, Symbicort$19$30,63947 claims
AbbVieSynthroid$13$4,285112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 112 cardiovascular disease providers in New Hampshire.

Other cardiovascular disease in Laconia

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →